BAX — Baxter International price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $25.79
- YTD price return
- +34.96%
- YTD total return
- +35.14%
- Market cap
- 13.3B
- Enterprise value
- 21.9B
- Shares outstanding
- 517.3M
- 52W low
- $15.73
- 52W high
- $30.00
- From 52W high
- -14.03%
- From 52W low
- +63.95%
- 52W range
- 70%$15.73–$30.00
- Beta
- 0.59
Volume
- Rel volume
- 0.86×
- 30D volume
- 7.2M
- 30D $ vol
- 178M
Fundamentals
- Sales (ttm)
- 11.6B
- Sales/share
- $22.44
- EPS (ttm)
- -$1.40
- FCF (ttm)
- 1.1B
- FCF/share
- $2.20
- Book value/share
- $12.57
- Net margin
- -6.23%
- ROE
- -11.12%
- ROA
- -3.72%
- Debt / equity
- 1.45×
- Current ratio
- 1.79
Growth (CAGR, ttm) · 10Y
- Sales
- +5.34%+4.23%-1.39%+1.38%
- FCF
- +366.48%-4.60%-5.34%+2.07%
- Shares
- +0.64%+0.65%+0.66%-0.50%
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +4.67%+3.53%-2.03%+1.89%
- FCF/share
- +363.50%-5.24%-5.96%+2.59%
- Book value/share
- -10.78%-7.67%-6.42%-2.36%
- Dividend/share
- -94.13%-67.44%-47.98%-22.17%
- Price
- +43.47%-9.23%-19.86%-5.82%
- Total return
- +43.75%-7.53%-18.27%-4.36%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -18.4×
- P/OI (ttm)
- 1233.4×
- Fwd P/E
- 12.6×
- P/S (ttm)
- 1.1×
- P/B (mrq)
- 2.1×
- P/FCF (ttm)
- 11.7×
- EV/EBITDA (fy)
- 29.9×
- EV/Sales (ttm)
- 1.9×
- FCF yield (ttm)
- 8.52%
- Dividend yield (fwd)Div yield
- 0.16%
- Dividend yield (ttm)
- 0.16%
- Dividend/share (fwd)
- $0.04
- Buyback yield (realized, 1y)
- -0.64%
- Shareholder yield (realized, 1y)
- 0.23%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.76%
Vs own 10Y history
- P/E
- 96th
- P/OI
- 99th
- P/S
- 13th
- P/B
- 14th
- P/FCF
- 1st
Bar = where today’s multiple sits in BAX’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-06#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m10Y n/mYoY +30.8%EPS (diluted)
5Y n/m10Y n/mYoY n/mFree cash flow
5Y CAGR −22.1%10Y CAGR −9.1%YoY +255.6%TTM: operating cash flow $1.6B, capex −$503M
Q3 2026: operating cash flow $558M, capex −$110M
Shares (diluted)
5Y −0.8%10Y −6.6%YoY +1.2%Dividend per share
5Y CAGR −11.4%10Y CAGR −8.5%YoY −94.1%About Baxter International#
Data provided bySource: Twelve DataBaxter International Inc. is a global healthcare company focused on providing essential medical products and technologies used in hospitals, clinics, surgery centers, pharmacies, and home-care settings. Baxter International Inc. develops and supplies infusion systems, sterile intravenous solutions, injectable pharmaceuticals, parenteral nutrition therapies, advanced surgery products, patient monitoring and diagnostic technologies, smart beds, and respiratory care devices. The company also supports renal and acute care through therapies and connected solutions that help clinicians deliver treatment across a wide range of care environments. Its portfolio is designed to support everyday healthcare delivery, from critical care and procedural settings to long-term and ambulatory care. Baxter International Inc. plays an important role in the medical technology market by supplying products that are widely used in routine treatment, life-sustaining therapy, and hospital infrastructure.
Deerfield, IL·37,500 employees·Medical Instruments & Supplies·baxter.com·As of Oct 28, 2026
Recent filings#
- Oct 29Earnings · Earnings release — EPS $0.58 vs $0.51 est. (+13.7%); revenue $2.98B (+5% y/y) 7.7%
- Aug 198-K · BAXTER APPOINTS JOHN ROGERS CHIEF FINANCIAL OFFICER
- Aug 188-K · BAXTER ANNOUNCES EARLY TENDER RESULTS AND UPSIZING OF PREVIOUSLY ANNOUNCED CASH TENDER OFFERS
- Aug 48-K · BAXTER ANNOUNCES CASH TENDER OFFERS
- Jul 30Earnings · Earnings release — EPS $0.56 vs $0.36 est. (+55.6%); revenue $2.96B (+5% y/y) 8.0%
ETFs holding BAX#
28 of the 193 ETFs ChartRow carries live hold BAX. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| RSP | Invesco S&P 500 Equal Weight ETF | 0.2% |
| VBR | Vanguard Small-Cap Value ETF | 0.2% |
| XLV | Health Care Select Sector SPDR Fund | 0.2% |
| VHT | Vanguard Health Care ETF | 0.2% |
| VB | Vanguard Small-Cap ETF | 0.1% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.1% |
| IWR | iShares Russell Midcap ETF | 0.1% |
| VYM | Vanguard High Dividend Yield ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +16.98% | -0.79% |
| JNJ | Johnson & Johnson | +8.42% | +1.43% |
| ABBV | AbbVie Inc. | +9.23% | +1.07% |
| MRK | Merck & Co. Inc. | +3.37% | -0.14% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +4.74% | -0.40% |
| NVS | Novartis AG | +15.46% | +0.38% |
| TMO | Thermo Fisher Scientific Inc. | +5.81% | +2.63% |
| AMGN | Amgen Inc. | +14.36% | +0.03% |
